Instead of a four-drug combination regimen (i.e., ICI + Bev + platinum-based chemotherapy), a three-drug combination regimen of Chemo+ICIs could serve as an alternative treatment option for patients with EGFR-mutated, EGFR-TKI-resistant NSCLC, particularly for those who were unable to tolerate Bev due to adverse events such as hypertension and bleeding risk. This evidence concerns the gene EGFR and non-small cell lung carcinoma.